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Oxytocin is a neuropeptide regulating social-affiliative and reproductive behaviour in mammals.
Despite robust preclinical evidence for the antinociceptive effects and mechanisms of action of
exogenous oxytocin, human studies have produced mixed results regarding the analgesic role of
oxytocin and are yet to show a specific modulation of neural processes involved in pain percep-
tion. In the present study, we investigated the analgesic effects of 40 IU of intranasal oxytocin
in 13 healthy male volunteers using a double-blind, placebo-controlled, cross-over design and
brief radiant heat pulses generated by an infrared laser that selectively activate Ad- and C-fibre
nerve endings in the epidermis, at the same time as recording the ensuing laser-evoked poten-
tials (LEPs). We predicted that oxytocin would reduce subjective pain ratings and attenuate the
amplitude of the N1, N2 and P2 components. We observed that oxytocin attenuated perceived
pain intensity and the local peak amplitude of the N1 and N2 (but not of P2) LEPs, and
increased the latency of the N2 component. Importantly, for the first time, the present study
reports an association between the analgesic effect of oxytocin (reduction in subjective pain rat-
ings) and the oxytocin-induced modulation of cortical activity after noxious stimulation (attenu-
ation of the N2 LEP). These effects indicate that oxytocin modulates neural processes
contributing to pain perception. The present study reports preliminary evidence that is consistent
with electrophysiological studies in rodents showing that oxytocin specifically modulates
Ad/C-fibre nociceptive afferent signalling at the spinal level and provides further specificity to
evidence obtained in humans indicating that oxytocin may be modulating pain experience by
modulating activity in the cortical areas involved in pain processing.
Key words: oxytocin, nociception, analgesia, laser-evoked potentials, EEG
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Oxytocin is a neuropeptide synthesised in the hypothalamus. It is
independently released into the bloodstream, exerting hormonal
effects on diverse physiological functions (1), and in the central
nervous system, exerting neuromodulatory effects on widely dis-
tributed oxytocin and vasopressin receptors (2,3). Oxytocin affects
reproductive and social-affiliative behaviours, including neuropro-
tective (4) and analgesic (5) roles during birth.
Robust preclinical evidence has demonstrated that exogenous
oxytocin has antinociceptive effects and has identified plausible
underpinning mechanisms (6). One mechanism involves the engage-
ment of GABA-mediated inhibitory circuits at the superficial layers
of spinal cord dorsal horn neurones, which express oxytocin
receptors (7) and receive direct projections from hypothalamic oxy-
tocin neurones (8,9), reducing Ad/C-fibre afferent signalling and
ascending nociceptive input (10–14). Additional mechanisms involve
the engagement of the endogenous opioid (15,16) and cannabinoid
(17) systems modulating nociception.
These findings, strengthened by initial evidence from open-label
clinical reports indicating that oxytocin produced analgesia in clini-
cal cases (16,18), led to the hypothesis that oxytocin has analgesic
effects in humans. However, double-blind, placebo-controlled stud-
ies have produced mixed results. In clinical groups, some reports
suggested that a single intranasal oxytocin dose provided headache
relief (19) and that an i.v. oxytocin infusion decreased colonic
visceral perception in patients with irritable bowel syndrome (20).
However, other studies administering intranasal oxytocin daily from
3 to 13 weeks in patients with chronic syndromes did not show
any analgesic effects (21,22).
Experimental studies on healthy volunteers using acute noxious
electrical, contact heat and cold-pressor stimuli have produced fur-
ther conflicting results. Most reports have not demonstrated any
specific antinociceptive properties for oxytocin (23–25), including a
phase 1 open-label trial using intrathecal administration (26). By
contrast, Rash and Campbell (27) reported that intranasal oxytocin
reduced the perception of pain intensity and unpleasantness. How-
ever, because 70% of the sample correctly identified the treatment
that they received (possibly as a result of the use of a saline spray
as placebo), the observed analgesic effects of oxytocin could have
been partially a result of the potentiating effects of oxytocin on
placebo analgesia (24).
In the present study, we investigated the effects of 40 IU of
intranasal oxytocin on pain perception and its neural correlates
using healthy male volunteers and a double-blind, placebo-con-
trolled cross-over design. We used brief radiant heat pulses gener-
ated by an infrared laser that selectively activate Ad and C-fibre
nerve endings in the epidermis (28). The use of noxious stimuli that
specifically engage Ad/C-fibre nociceptive afferent signalling in
humans may provide a promising tool for illuminating the antinoci-
ceptive properties of oxytocin given evidence from electrophysiolog-
ical studies in rodents suggesting that oxytocin specifically
modulates Ad/C-fibre nociceptive afferent signalling (10,29). We
predicted that intranasal oxytocin would reduce subjective pain
reports and attenuate the amplitude of the N1, N2 and P2 laser-
evoked potentials (LEPs) reflecting the cortical response to nocicep-
tive input (30). Latencies were also examined in an exploratory
manner. LEPs reflect temporally distinct cortical processes specifi-
cally evoked by the activation of Ad-fibres (31) and are differen-
tially modulated by cognitive (32–34) and pharmacological (35)
interventions. Hence, LEPs are ideally suited for investigating the
mechanisms underpinning the analgesic effects of oxytocin on pain
perception. Given the likely effect of oxytocin on the stress
response (36), we also measured salivary cortisol levels to control
for stress-related physiological changes contributing to the pre-
dicted analgesic effect.
Materials and methods
Participants
Thirteen right-handed, healthy adult male volunteers participated in the
present study (mean  SD age: 25.69  4.85 years). Participants did not
have a history of medical, neurological or psychiatric problems and were
screened for current psychiatric conditions using the Symptom Checklist-
90-R (37) and Beck’s Depression Inventory II (38). They did not take any
prescribed drugs, tested negative on a urine screening test for drugs of
abuse, and consumed < 28 units of alcohol per week and < 5 cigarettes
per day. Both parents were white European to reduce genetic background
variability (39). Day-of-testing lifestyle changes included abstaining from
alcohol and heavy exercise for 24 h and not having any beverages or
food in the 2 h before the testing session. Data for 18 participants were
excluded for showing very low and inconsistent hand temperatures
between testing sessions (< 27 °C) as a result of a central heating fault
in the laboratory, with six of these not showing any discernible LEPs at
baseline recordings (one participant also scored above the cut-off score
of 13 on Beck’s Depression Inventory). Although skin temperatures were
recorded as a result of their importance for pain perception, the risk of
not maintaining consistent skin temperatures within a specific range
across active and placebo conditions had not been fully appreciated at
the time because, during our pilot studies, the temperature of the labo-
ratory was well controlled. Given the close association between initial
skin temperature and the required energy level to reach a given effect,
initial skin temperature and consistency across testing conditions in stud-
ies investigating the antinociceptive properties of drugs are recognised as
important factors that could confound treatment effects (40–46). We
aimed to maintain a dataset of at least N > 11 [comparable to other
LEP studies (47), including studies using LEPs to investigate the analgesic
properties of drugs (35): N = 12], choosing 27 °C as the cut-off temper-
ature (a temperature as close to the bottom end of a previously reported
typical range as possible, between 28.5 and 33.6 °C) (47). This criterion
was set post-hoc but before the analysis of results. Participants provided
their written informed consent and received compensation for their time.
King’s College London Research Ethics Committee (PNM/10/11-160)
approved the study.
Nociceptive stimulation
We used an infrared neodymium:yttrium-aluminum-perovskite (Nd:YAP;
Electronical Engineering, Florence, Italy) laser with a wavelength of 1.34 lm
to generate radiant heat pulses. The pulses had duration of 4 ms, were
transmitted via an optic fibre cable, and were focused by a lens to a spot
diameter of 6 mm at the target site on the dorsum of the left hand. The
spot location was changed after each pulse to avoid nociceptor fatigue and
sensitisation (48).
Oxytocin administration
Participants self-administered 40 IU of intranasal oxytocin (Syntocinon;
Novartis, Basel, Switzerland) or placebo (same composition as Syntocinon
except for oxytocin). They applied one puff containing 4 IU of oxytocin (or
placebo) every 30 s, alternating between nostrils. The administration phase
lasted approximately 9 min including a 3-min rest at the end. Participants
reported no side effects during or immediately after the experimental proce-
dure.
Experimental design
We adopted a double-blind AB/BA (oxytocin-placebo/placebo-oxytocin)
cross-over design with baseline measurements before each treatment (49) to
test for treatment effects. We obtained baseline measurements before each
treatment because they can contain important background information on
each participant and increase the precision of the analyses of treatment
effects (49). Participants were randomly allocated to a treatment sequence,
receiving each treatment on separate visits (mean  SD: 13.15  6.05 days
apart) at the same time of the day. Of the 13 participants, seven received
oxytocin in the first visit and six in the second visit. Infrared laser stimuli
were delivered as part of a battery of tasks and questionnaires, and partici-
pants were informed that we investigated the effects of a neuropeptide on
brain activity and on a range of mental processes. All participants remained
blind with respect to the name of the neuropeptide that they received and
also the true purpose of the study until debriefing at the end of the second
visit.
© 2015 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd
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Procedures
Participants were seated at a desk facing a computer monitor framed by a
screen. The laser equipment and the experimenter were seated behind the
screen to prevent visual contact with the participant. Participants rested
their left forearm on the desk, extending it through an opening on the
screen so that they did not have visual contact with the stimulated hand.
The same testing protocol was followed during each visit. Initially, partici-
pants experienced a series of pulses of increasing energy to familiarise them
with the equipment, the procedures and the sensations, as well as to deter-
mine their individual pain tolerance levels. Participants were asked to focus
on the pinprick sensation generated by the activation of the Ad fibres and
rate it on an 11-point visual analogue scale (VAS) with anchors (0 = ’no
pinprick sensation’ to 10 = ’the worst pinprick sensation imaginable’). Partic-
ipants then received three computer-administered mini-blocks of pulses,
each consisting of all laser intensities, in steps of 0.25 J, up to their individ-
ually determined tolerance limit, and were asked to provide a VAS rating
after each pulse. These were used to determine separately, for each partici-
pant, the experimental stimulus intensity corresponding to a clearly per-
ceived pinprick of moderate intensity, and the control stimulus intensity,
corresponding to the energy level at the threshold of perception. The same
stimulus intensities were used in the oxytocin and placebo visits for each
participant. Subsequently, we fitted the electroencephalogram (EEG) cap.
Participants then received two blocks of nociceptive stimuli: one immediately
before receiving treatment (‘baseline’) and one approximately 45–50 min
after treatment onset (‘post-treatment’), when their EEG was being recorded.
Each block consisted of 50 experimental and 20 control trials presented in
pseudorandom order. Hand skin temperature was recorded with an infrared
thermometer at the beginning of each block. Each trial began with a fixation
cross (displayed for 6 s), with a laser pulse being delivered midway (at 3 s).
Then the word ‘Rating’ appeared on the screen for 3 s as a cue for partici-
pants to give their VAS rating orally using the same anchors as above. Each
trial ended with a jittered inter-trial interval (0–5 s; mean trial duration was
11.43 s). The mean  SD experimental stimulus intensity was
4.12  0.44 J, range 3.35–4.5 J) and the mean  SD control intensity was
1.83  0.40 J, range 1.5–2.5).
Salivary cortisol
Salivary samples were obtained via passive drool to measure the unbound
form of cortisol (50) at four time points: two samples were obtained during
set-up and averaged to obtain cortisol levels at ‘session onset’ (Table 1); one
sample at the end of the baseline nociceptive experimental block (before
treatment); and a final sample at the end of the post-treatment experimen-
tal nociceptive block (approximately 60–65 min after treatment onset). Sali-
vary samples were frozen at 80 °C until assayed. Free cortisol
concentration was measured using the Salimetrics Elisa kit (Salimetrics Eur-
ope Ltd, Newmarket, UK), which comprises a competitive immunoassay
specifically designed and validated for the quantitative measurement of sali-
vary cortisol. The intra-assay coefficient of variation (CV) was between
3.35% and 3.65%, and the inter-assay CV was between 3.75% and 6.41%.
The sensitivity of the assay was 0.083 nmol/l.
LEPs
Brief radiant heat pulses generated by an infrared laser selectively activate
Ad- and C-fibre skin nociceptors and generate a series of transient, time-
locked brain responses (51) that appear as deflections in the EEG and
specifically reflect the activation of Ad fibres (52). LEPs comprise a negative-
positive deflection, maximal at the scalp vertex (N2-P2 wave, peaking at
200–350 ms when stimulating the hand dorsum), and a preceding smaller
negative deflection maximal at the contralateral temporal electrodes (N1
wave, peaking at approximately 160 ms) (48).
EEG recording
EEG data were collected using a 64-channel Neuroscan Quik-cap elasticised
cap with passive AgCl electrodes and recorded using SCAN, version 4.3 (Com-
pumedics, Ltd, Charlotte, NC, USA). Data were collected from 64 electrodes
positioned on the scalp in accordance with the International 10–20 system.
A bipolar electrode on the earlobes was used as the recording reference and
additional electrodes on the mastoids were used to serve as reference elec-
trodes for the analyses. The electrooculogram was recorded by placing a
bipolar electrode above and below the right eye and two electrodes to the
left and right of each eye. Impedances were kept below 5 kΩ. The data were
sampled at 5000 Hz.
EEG analysis
EEG data were processed using the MATLAB (R2011a; MathWorks Inc., Natick,
MA, USA) open-source toolboxes EEGLAB (53) and ERPLAB (54). We focused our
analyses on the experimental trials because the control trials were included
to decrease the predictability of the experimental stimuli. EEG data were
Table 1. Raw Mean Visual Analogue Scale (VAS) Ratings, Mean Local Peak Amplitudes and Latencies of the N1, N2 and P2 Laser-Evoked Potentials (LEPs),
Salivary Cortisol Levels and Skin Temperatures at the Dorsum of the Left Hand from the Baseline and the Post-Treatment Blocks.
Session onset Baseline Post-treatment
Placebo visit,
mean  SD
Oxytocin visit,
mean  SD
Placebo visit,
mean  SD
Oxytocin visit,
mean  SD
Placebo visit,
mean  SD
Oxytocin visit,
mean  SD
N1 local peak amplitude (lV) – – 9.95  4.31 9.62  3.93 9.56  4.02 8.16  2.88
N1 local peak latency (ms) – – 186.14  21.64 192.37  21.18 185.34  18.52 193.80  19.41
N2 local peak amplitude (lV) – – 12.58  7.10 12.01  6.76 11.65  7.39 9.67  5.45
N2 local peak latency (ms) – – 217.79  19.68 218.72  25.53 215.30  21.08 225.41  23.65
P2 local peak amplitude (lV) – – 11.17  5.56 11.29  4.75 10.68  5.22 9.68  3.10
P2 local peak latency (ms) – – 333.28  28.31 335.91  36.69 334.70  27.37 339.72  34.36
VAS ratings – – 3.83  1.47 3.32  1.29 3.35  1.44 3.12  1.50
Salivary cortisol (nmol/l) 5.56  3.34 5.75  2.78 4.75  3.07 4.14  2.18 3.74  2.44 4.16  2.73
Skin temperature (°C) – – 31.09  1.99 30.69  1.80 30.58  1.82 29.79  2.10
© 2015 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd
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down-sampled to 250 Hz and re-referenced using the averaged recordings
from the mastoid electrodes before applying a high-pass filter of 0.4 Hz.
The EEG was then segmented into 500- to 1000-ms epochs relative to the
onset of the stimulus and a 30 Hz low-pass filter was applied. Epochs from
the baseline and post-treatment blocks were concatenated and trials with
gross artefacts (exceeding 400 lV) were removed. Ocular artefacts were
removed using independent component analyses (‘runica’ algorithm) in
EEGLAB. Prototype blinks and saccades were identified following visual inspec-
tion and the CORRMAP utility (55) was used to identify matching artefacts
across the datasets for removal. Finally, epochs containing artefacts exceed-
ing  100 lV were removed, then epochs were resegmented to 200 to
800 ms and baseline-corrected (200 to 0 ms). Fewer than 10% of trials
were removed from each dataset. The ERPLAB measurement tool was used to
measure the local peak amplitude and latency of the LEPs. Average wave-
forms for each component time-locked to stimulus onset were computed
for each block (baseline, post-treatment) and treatment condition (oxytocin,
placebo). The peak-to-baseline amplitude and the latency of the N2 (latency
window: 100–350 ms) and P2 (latency window: 250–420 ms) components
were measured at the Cz electrode using an average reference, and those of
the N1 component (latency window: 0–270 ms) were measured at the C4
electrode (contralateral to the stimulated hand), using the Fz electrode as
reference.
Statistical analysis
Our primary outcome variables were the mean VAS ratings and the mean
local peak amplitudes of the N1, N2 and P2 LEPs for each block. Compo-
nent latencies and salivary cortisol levels (nmol/l) were secondary outcome
variables. We tested for treatment effects (oxytocin versus placebo) using
the analysis of covariance (ANCOVA) approach described by Senn (49) and
Metcalfe (56) for the analysis of AB/BA cross-over designs with baseline
measurements before each treatment. If T = active treatment (intranasal
oxytocin), C = control treatment (placebo), XT and XC are the corresponding
baseline measurements, and YT and YC the corresponding post-treatment
measurements, using the regression command in STATA, version 13 (Stata-
Corp, College Station, TX, USA), we implemented the ANCOVA model:
(YTi  YCi) = bT + c(XTi  XCi) as described by Senn (49) and Metcalfe
(56), separately, for each outcome variable. The intercept term in this
model tests for the treatment effect. In the regression model, we also
included a binary explanatory variable representing treatment sequence (AB
or BA) for each measure where there was a significant period effect
(which might reflect a general tendency, irrespective of treatment). We
tested for period effects (i.e. changes in measurements across visits,
obtained by subtracting post-treatment measurements at the first visit
from post-treatment measurements at the second visit) by regressing per-
iod differences on treatment sequence. Additionally, we computed base-
line-corrected basic estimators of treatment effects by subtracting the
corresponding baseline differences weighted by their regression slope. As a
control, we tested for treatment effects on skin temperatures using the
same approach; we also used paired-sample t-tests to check separately for
skin temperature differences between baseline and post-treatment mea-
surements under oxytocin and placebo. Finally, we tested for time effects
on salivary cortisol levels (to investigate whether the administration of the
nociceptive stimuli increased cortisol levels) using a 3 (Time: session onset,
before treatment, post-treatment) by 2 (Treatment: oxytocin, placebo) anal-
ysis of variance (ANOVA) model implemented in STATA, version 13 (StataCorp)
using the ‘regression’ command and robust variance estimation (‘cluster’
option) to correct for data dependence (5) (as a result of the within-sub-
jects factors). We conducted statistical inferences using nonparametric
bootstrapping estimation (1000 repetitions), which does not make distribu-
tional assumptions on the data (57).
Results
Table 1 presents raw mean VAS ratings, mean local peak amplitudes
and latencies of the N1, N2 and P2 LEPs, salivary cortisol levels and
skin temperatures at the dorsum of the left hand from the baseline
and the post-treatment blocks. Table 2 summarises the results of
the regression analyses examining the effects of intranasal oxy-
tocin, compared to placebo, for each outcome variable.
LEPs and VAS scores
Intranasal oxytocin significantly reduced subjective VAS ratings, as
well as N1 and N2 local peak amplitudes, and increased N2 local
peak latency (Fig. 1 and Tables 1 and 2). Baseline-corrected treat-
ment effect estimators for VAS ratings were significantly correlated
with the N2 (r = 0.57, P = 0.042) but not the N1 (r = 0.47,
P = 0.11) local peak amplitudes, although both correlations were
moderate and in the expected direction (i.e. the greater the oxy-
tocin-induced reduction in VAS ratings the greater the oxytocin-
induced attenuation of the LEP amplitude). Period effects were sig-
nificant only for the post-treatment P2 local peak latency
(b = 32.62, SE = 11.82, Z = 2.76, P = 0.019) and the VAS ratings
(b = 1.55, SE = 0.65, Z = 2.40, P = 0.035) and hence included in
the corresponding regression models (as explained in the Statistical
analysis).
Skin temperature
Skin temperatures ranged within expected levels for studies using
laser-generated radiant heat stimuli (47). There was no treatment
effect on skin temperatures (Table 2). Furthermore, skin tempera-
tures did not differ between treatments across the baseline
(t12 = 0.51, P = 0.62) or the post-treatment blocks (t12 = 1.10,
P = 0.29).
Salivary cortisol levels
There was no treatment effect on salivary cortisol levels (Table 2).
An ANOVA showed a significant effect of Time v22 = 11.14, P = 0.004,
with salivary cortisol levels decreasing between session onset and
post-treatment block (Table 1). Post-hoc tests showed that salivary
cortisol levels were significantly lower at the end of the post-treat-
ment block compared to session onset (v21 = 11.12, P < 0.001) but
not compared to the end of the pre-treatment block (v21 = 3.02,
P = 0.082); no significant difference was observed between the end
of the pre-treatment block and session onset (v21 = 2.01, P = 0.16).
Discussion
In this double-blind, placebo-controlled, cross-over study, we stimu-
lated Ad- and C-fibre skin nociceptors in the dorsum of the hand
using infrared laser radiant heat stimuli in healthy male volunteers.
We found that a single dose of intranasal oxytocin (40 IU) attenu-
ated both perceived pain intensity and laser-evoked cortical
© 2015 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd
on behalf of British Society for Neuroendocrinology
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responses. Specifically, intranasal oxytocin attenuated the local peak
amplitude of the N1 and N2 (but not of P2) LEPs, and increased
the latency of the N2 component. Importantly, for the first time,
the present study reports an association between the analgesic
effect of oxytocin (reduction in subjective pain ratings) and the
oxytocin-induced modulation of cortical activity following noxious
stimulation (attenuation of the N2 LEP). These effects indicate that
oxytocin modulates neural processes contributing to pain percep-
tion and are discussed in turn below.
Subjective ratings
We observed a 7% reduction in subjective pain intensity ratings fol-
lowing intranasal oxytocin (compared to placebo). This effect is
smaller but comparable to a recent study showing that 40 IU of
intranasal oxytocin induced an 11% reduction in intensity ratings
following the application of cold-pressor pain on healthy volunteers
(27). Our studies differ not only in terms of pain modality, but also
in the timing of the intervention following oxytocin treatment. This
question has only recently began to be addressed, with a recent
study suggesting changes in regional cerebral blood flow (rCBF) in
the resting state peak at 30–42 min from the end of intranasal
oxytocin (40 IU) administration (58). Indeed, in the study reporting
the larger reduction in pain intensity ratings (27), the intervention
commenced at 20 min post-oxytocin treatment and partially over-
lapped with the temporal window during which the effects of
intranasal oxytocin in the brain are maximal, whereas, in the pre-
sent study, the intervention spanned 45–60 min post treatment.
Thus, our study confirms that future research should consider the
temporal dynamics of the pharmacodynamic effects of oxytocin in
order to illuminate its antinociceptive properties (58).
LEPs and mechanisms mediating the effects of oxytocin on
pain
We further observed that intranasal oxytocin specifically modulated
the N1 and N2 but not the P2 LEPs. Although the functional signif-
icance of LEPs is not yet clearly understood (59), the cortical pro-
cesses generating LEPs are largely related to the perception of
salient changes in the sensory environment (59,60), and contribute
to the perception of pain (61,62). The early N1 component, reflect-
ing the activity of cortical generators in the contralateral opercu-
loinsular and primary somatosensory cortices (30,63), is largely
driven by the magnitude of the ascending nociceptive input, repre-
senting an early stage of sensory processing before the perceptual
outcome of the nociceptive input is determined (48,64,65). The later
N2 and P2 components reflect cortical generators in the insular
and anterior cingulate cortices (30,63), and also relate to the inten-
sity of noxious stimuli, although they largely represent cortical
mechanisms that determine the subjective experience of pain (48).
Our observation that intranasal oxytocin reduced the amplitude
of the N1 and N2 but not the P2 cortical responses suggests that
it affects specific processes contributing to pain experience. First,
the reduction in N1 and N2 amplitudes (and increase of N2 laten-
cies) is consistent with effects of oxytocin at spinal levels, affecting
the coding of noxious stimulus intensity and the ensuing experi-
ence of pain. Indeed, animal studies have shown that oxytocin can
specifically reduce Ad/C-fibre afferent signalling and ascending
nociceptive input at the level of spinal cord dorsal horn neurones
by engaging GABA-mediated inhibitory cellular mechanisms
(10–14,29). Additionally, oxytocin may be modulating the pain
experience in humans by modulating activity in cortical areas
involved in pain processing. In humans, intranasal oxytocin has
Table 2. Regression Analyses Showing the Effect of Intranasal Oxytocin (Compared to Placebo) for Each Outcome Variable.
b 95% CIb SE Z P
Estimated
treatment
effectc dd
N1 local peak amplitude 1.65 0.11, 3.20 0.79 2.09 0.036 1.77 0.63
N1 local peak latency 1.06 5.49, 7.62 3.34 0.32 0.75 3.08 0.26
N2 local peak amplitude 1.79 0.27, 3.32 0.78 2.30 0.021 1.98 0.73
N2 local peak latency 10.03 3.25, 16.81 3.46 2.90 0.004 10.11 0.83
P2 local peak amplitude 1.07 2.51, 0.36 0.74 1.46 0.145 0.99 0.38
P2 local peak latencye 1.99 3.70, 7.68 2.90 0.69 0.493 5.02 0.49
VAS ratingse 1.27 2.25, 0.29 0.50 2.53 0.011 0.23 0.20
Salivary cortisol 0.62 0.74, 1.98 0.69 0.90 0.37 0.42 0.18
Including initial session
recordings
0.52 0.71, 1.76 0.63 0.83 0.41 0.42 0.20
Skin temperature 0.51 1.40, 0.38 0.45 1.13 0.26 0.78 0.46
VAS, visual analogue scale.
aThe presented statistics correspond to the intercept of the regression line that estimates the effect of interest.
b95% confidence interval for the b coefficient.
cEstimated marginal mean for the treatment effect.
dCohen’s d (estimated treatment effect/SD) (90).
eRegression models included treatment sequence (AB/BA) as a covariate because of the presence of significant period effects, as described in the Statistical
analysis and reported in the Results.
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been shown to increase rCBF, and hence neuronal activity, in corti-
cal areas directly implicated in the processing of nociceptive input
and the experience of pain, as well as in the descending modula-
tion of nociceptive input, such as the frontoparietal opercula, the
insula and the anterior cingulate cortex (58,66,67). Changes in
neuronal activation in these cortical areas have been shown to
modulate the evoked brain responses to transient nociceptive input
(68). For example, the observation of emotionally conflicting infor-
mation that activates the anterior cingulate cortex modulates the
perception of pain and specifically prevents the full expression of
the N2 component (reducing its amplitude) (68). Consistent with
this and the role of N2 in the experienced pain intensity, we
observed that the oxytocin-induced reduction in pain ratings corre-
lated with the oxytocin-induced reduction in N2 amplitude. The lack
of intranasal effects of oxytocin on the later P2 component sug-
gests that it may not have influenced the perceived salience of the
noxious stimuli. The P2 component has been shown to be modu-
lated specifically by factors reflecting the salience of noxious stimuli
(e.g. stimulus probability) (33,59,69) and to reflect multimodal
(rather than somatosensory-specific) processes (61).
The intranasal dose administered in the present study has been
associated with changes in central function in humans (58), and
similar or smaller doses of oxytocin or vasopressin (24–48 IU for
oxytocin; 40–80 IU for vasopressin) have been associated with ele-
vations in peptide levels in the cerebrospinnal fluid in humans or
macaques of no more than approximately 55 pg/ml in actual levels
(70–74), or of up to 0.005% of the administered dose (75). It is
possible that the observed effects in the present study could be at
least partially explained by elevations in central levels of oxytocin,
although it is not clear to what extent this elevation reflects
endogenous or exogenous oxytocin and, if the latter, what the
mechanisms of absorption may be. However, it remains unknown
how much oxytocin must enter the brain in primates for a beha-
vioural effect to be observed; in smaller animals, 1 ng has been
reported as the lowest i.c.v. dose shown to elicit a behavioural
effect (75). Additionally, it is also possible that the antinociceptive
effects of intranasal oxytocin observed in the present study are
explained by the activation of peripheral receptors, mainly the vaso-
pressin 1A receptor (76). Future studies will need to specifically
address the mechanism mediating the antinociceptive effects of
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Fig. 1. Grand mean of laser evoked potentials (LEPs) after stimulation of the left-hand dorsum (N = 13) at baseline and after receiving treatment (oxytocin
or placebo). x-axis: time (ms); y-axis, amplitude (lV). Top: N1 wave recorded at the temporal region contralateral to the stimulated site (C4 versus Fz). Bottom:
N2/P2 wave recorded at the vertex (Cz versus average reference). Full waveforms are LEPs obtained after treatment (oxytocin: red; placebo: blue). Dashed
waveforms are LEPs obtained before treatment (baseline). There was a significant reduction in N1 local peak amplitude (P = 0.036) following oxytocin treat-
ment (compared to placebo and controlling for baseline). There was also a significant reduction in N2 local peak amplitude (P = 0.021) and an increase in N2
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oxytocin in humans; for example, by administering antagonists to
block peripheral oxytocin or vasopressin receptors (75).
Impact on the stress response
A further mechanism postulated to potentially mediate intranasal
effects of oxytocin on pain sensitivity in humans involves the miti-
gation of psychological factors such as negative mood, anxiety and
the stress response to pain (27). In the present study, we did not
observe an effect of oxytocin on salivary cortisol levels. This might
be because our participants did not find our pain paradigm (involv-
ing a highly controlled stimulus) sufficiently stressful in that there
was a reduction in salivary cortisol levels over time irrespective of
treatment condition. However, a review of human studies examin-
ing the effect of oxytocin on cortisol suggests that oxytocin may
exert both anxiogenic and anxiolytic effects, depending on a variety
of individual and context variables (77,78), which are not always
reflected in changes in cortisol levels (79,80). Furthermore, existing
studies have either failed to show a mitigating effect of oxytocin
on negative mood (27) or have shown that such an effect was not
related to the pain experience (23).
Mediating social effects on pain
The analgesic effects of exogenous oxytocin in humans identify the
oxytocin system as a plausible neural mechanism for the transduc-
tion of the effects of social support into the neural and physiologi-
cal changes that modulate the experience of pain in humans (81),
and such a hypothesis needs to be addressed in future research.
Social factors, such as the supportive presence of others, have been
shown to modulate the experience of pain (82). Interaction with
other humans, including warm interpersonal contact (83,84) or the
perception of trust (85), can result in the release of endogenous
oxytocin. Preclinical studies demonstrate that manipulations involv-
ing bodily contact such as massage can induce anti-nociceptive
effects in rodents similar to those elicited by exogenous oxytocin,
by triggering the endogenous oxytocin system (86).
Limitations
A number of limitations characterise the present study. First, we
focused on male participants because some degree of sexual
dimorphism in the oxytocin system may be expected (87). Hence,
our findings cannot be readily extrapolated to women. Second, we
used the maximal oxytocin dose safely administered to humans
(88) and a high intensity of the noxious stimulus because our
aim was to assess the presence of analgesic properties of intrana-
sal oxytocin in humans. Future studies should systematically
examine a wider range of dosages and intensities of noxious
stimuli, as well as include clinical populations, aiming to charac-
terise the analgesic properties and potential clinical relevance of
intranasal oxytocin. Third, future studies should explicitly investi-
gate whether oxytocin influences the salience of noxious stimuli
and whether it modulates pain-specific processing or sensory pro-
cessing in general (23). Fourth, because we did not measure heart
rate variability in the present study, we could not determine
whether the analgesic effects of intranasal oxytocin were at least
partially mediated by oxytocin-induced modulation of heart rate
reactivity to pain (27). Last but not least, although the present
study investigated an effect of oxytocin on a phenotype that
could be reasonably expected on the basis of animal research,
given the small sample size, it is possible that the observed treat-
ment effect is overestimated (89). Our findings will need to be
replicated in future studies that are adequately powered to detect
even smaller treatment effects.
Conclusions
By selectively stimulating subcutaneous Ad- and C-fibres with an
infrared laser and recording the EEG in participants, we provide
preliminary evidence indicating that a single intranasal oxytocin
dosage (40 IU) attenuated pain intensity ratings and differentially
modulated the ensuing cortical LEPs in humans. Our findings are
consistent with robust preclinical evidence on the antinociceptive
properties of oxytocin and highlight potential neural mechanisms
mediating the analgesic effects of oxytocin in humans.
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